Once-Nightly Lumryz Attracts Over 1,200 Narcolepsy Patients Since June Launch
Avadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
